Theranomics is involved in precision oncology and personalized medicine, self-described.

Theranomics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics, Inc. Common Stock

Precision Medicine Group is involved in drug development and access through the discipline of precision medicine, utilizing insights and specialized capabilities to enhance clinical research, manufacturing, and commercial success.

Precision Medicine Group

Rayca Precision is engaged in precision drug discovery and clinical research, focusing on advancements in clinical and preclinical studies through AI and bioinformatics.

Metric
Company Name	Theranomics	Acrivon Therapeutics, Inc. Common Stock	Precision Medicine Group	Rayca Precision
Symbol		ACRV
MSH ID	BIO:THERANOMICS	COM:ACRIVON	COM:PRECISIONMEDICINEGRP	COM:RAYCABIO
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	MX	US	US	US
Stage
Employee Count		58
Website	theranomics.bio	acrivon.com	precisionmedicinegrp.com	raycabio.com
LinkedIn
Founders

Metric
Market Cap		221.08M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

THER

BIO:THERANOMICS

Theranomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue